Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday

U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session.

U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session.

  • Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) shares dipped 29.9% to $14.59 after Teva Pharmaceuticals stated it plans to sell a generic version of Catalyst’s FIRDAPSE in the United States.
  • Eargo, Inc. (NASDAQ:EAR) dropped 15.1% to $12.35 after jumping 26% on Friday. The company recently effected a 1:20 reverse stock split.
  • Eve Holding, Inc. (NYSE:EVEX) declined 13.7% to $6.33. Eve Holding recently reported a third-quarter FY22 net loss of $(36.7) million versus a loss of $(3.8) million in 3Q21.
  • AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) dipped 12% to $8.48. AnPac Bio-Medical Sciences announced receipt of staff delisting determination from the Nasdaq.
  • Xylem Inc. (NYSE:XYL) declined 9.5% to $99.70 after the company announced it would acquire Evoqua for $7.5B of Xylem stock.
  • Bed Bath & Beyond Inc. (NASDAQ:BBBY) fell 9.2% to $3.04. The company received a Nasdaq notice regarding a delayed quarterly report. It was also reported the company has hired a legal advisor ahead of a potential bankruptcy filing.
  • Pharvaris N.V. (NASDAQ:PHVS) dropped 8.8% to $9.35.
  • Vigil Neuroscience, Inc. (NASDAQ:VIGL) fell 7.4% to $11.77.
  • Mammoth Energy Services, Inc. (NASDAQ:TUSK) dropped 6.9% to $6.64.
  • Oragenics, Inc. (NYSE:OGEN) dropped 5.8% to $7.80.

Check This Out: 3 Stocks Insiders Are Buying: Coinbase Global And More

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Enhertu Approved in the EU for Patients With HER2-Positive Metastatic Breast Cancer Treated With One or More Prior Anti-HER2-based Regimens

Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu across Europe to earlier use in HER2-positive metastatic breast cancer. Based on ground-breaking DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1).

AZN